GlassScriptPhysician profile
Jane N Gitau
NPI 1093198822
$5,053.08
in general payments reported to CMS, 2019-2025
34 companies · $905 in 2025
The $905 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $133 · 2022: $214 · 2023: $1,204 · 2024: $960 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,114.23 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $993.47 | 2019-2025 | Biktarvy |
| Abbvie INC. | $663.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $267.03 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Janssen Biotech, INC. | $206.41 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $204.91 | 2019-2025 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $175.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.28 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $130.51 | 2019-2024 | Wegovy, Saxenda |
| Astellas Pharma US INC | $112.64 | 2019-2022 | |
| Lilly USA, LLC | $111.44 | 2019-2025 | Mounjaro |
| Janssen Products, LP | $99.95 | 2019 | |
| Pfizer INC. | $98.00 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.85 | 2025 | Caplyta |
| Eisai INC. | $66.16 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.33 | 2022-2025 | Rexulti |
| Ardelyx, INC. | $55.53 | 2025 | Ibsrela |
| Abbott Laboratories | $43.14 | 2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $42.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.31 | 2019-2023 | Xarelto |
| Amgen INC. | $34.02 | 2019 | |
| Sumitomo Pharma America, INC. | $33.72 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $33.35 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $32.89 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $29.51 | 2022-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $25.61 | 2025 | Fanapt |
| Globus Medical, INC. | $21.05 | 2025 | Senza |
| Xeris Pharmaceuticals, INC. | $18.11 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $17.85 | 2025 | Rexulti |
| Vyera Pharmaceuticals, LLC | $17.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.27 | 2025 | Lifevest |
| Collegium Pharmaceutical, INC. | $14.66 | 2024 | Belbuca |
| Allergan, INC. | $13.60 | 2019 | |
| Mylan Specialty L.P. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Gitau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.